12:00 AM
Jul 13, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pralatrexate: Completed Phase IIa enrollment

Allos completed enrollment of 201 current/former cigarette smokers who have failed >=1 platinum-based chemotherapy in an international Phase IIb trial evaluating IV pralatrexate given on days...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >